# Amphivena Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/amphivena-therapeutics

- Industry: Pharmaceuticals
- Headquarters: San Francisco, US
- Website: www.amphivena.com
- Total disclosed funding: $28M
- Latest round: Series C (Sep 24, 2019)
- Investors on record: 12

## About

Amphivena Therapeutics, Inc. is a biotechnology company that focuses on developing innovative therapies for treating cancer and other diseases by harnessing the power of the immune system.Founded in 2012 in San Francisco, US, Amphivena Therapeutics, Inc. specializes in creating immunotherapies to combat cancer. The company's strategic focus has remained consistent since its inception. The CEO, Curtis Ruegg, leads the organization, which has raised a total of USD 23.30 mn in its Series C funding round as of September 24, 2019, with prominent investors including NanoDimension and Qiming Venture Partners. The total amount raised by the company stands at USD 23.30 mn, with a current valuation of USD 277.24 mn.Amphivena Therapeutics develops groundbreaking immunotherapeutic products aimed at treating cancer. Their flagship therapeutic candidates are designed to engage the immune system to target and eliminate cancer cells effectively, enhancing treatment outcomes for patients.Amphivena Therapeutics does not currently generate revenue from product sales, as the company is in the development phase of its therapeutic candidates. Funding obtained from investors supports research and development activities to advance their product pipeline.Following their Series C funding round in September 2019, which raised USD 62 mn, Amphivena Therapeutics, Inc. plans to utilize these funds to further advance its lead therapeutic candidate. The company is focused on progressing its clinical trials and exploring potential new products, with an emphasis on expanding its market presence in the oncology field.

## Funding rounds

- Series C, Sep 24, 2019, $23M — Industrial Investors, Qiming Venture Partners, AJU IB Investment, Tekla Capital Management, +ND Capital, MPM BioImpact, Korys, Kaitai Capital, Clough Capital Partners, Nawton Limited
- Series A, Jul 11, 2013, $4.2M — MPM BioImpact, Aeris Capital, Affimed GmbH

## Investors

- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series A, Series C
- Aeris Capital — Series A
- Affimed GmbH — Series A
- Industrial Investors (https://capitalatlas.ai/funds/industrial-investors) — Series C
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series C
- AJU IB Investment (https://capitalatlas.ai/funds/aju-ib-investment) — Series C
- Tekla Capital Management (https://capitalatlas.ai/funds/tekla-capital-management) — Series C
- +ND Capital (https://capitalatlas.ai/funds/nd-capital) — Series C
- Korys (https://capitalatlas.ai/funds/korys) — Series C
- Kaitai Capital (https://capitalatlas.ai/funds/kaitai-capital) — Series C
- Clough Capital Partners — Series C
- Nawton Limited — Series C